Other Investments	3 Months Ended
Mar. 31, 2025
Investments, All Other Investments [Abstract]
Other Investments	Other Investments In prior years the Company made minority ownership strategic investments. As of both March 31, 2025 and December 31, 2024, the aggregate carrying amount of the Company’s strategic investments in non-publicly traded companies was $19.0 million. These investments are measured at initial cost, minus impairment, if any, and plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Cumulative impairments of strategic investments in equity investments without readily determinable fair values still held as of both March 31, 2025 and December 31, 2024 were $23.0 million, reflecting the full impairment of two of the Company’s other investments in the first quarters of 2023 and 2024. As a part of the acquisition of each of the Company’s other investments, the Company determines whether an investment or other interest is considered a variable interest. As of both March 31, 2025 and December 31, 2024, the Company held an interest in one entity that was concluded to be a variable interest for which the Company was not the primary beneficiary as the Company did not have the power to direct the activities that most significantly impact the economic performance of the variable interest entity. As of both March 31, 2025 and December 31, 2024, the carrying value and maximum exposure to loss of the Company’s variable interests was zero. In connection with the preparation of the financial statements for the three months ended March 31, 2024, the Company performed a qualitative assessment of potential indicators of impairment and determined that indicators existed for one of its other investments with a carrying amount of $13.0 million. During the three months ended March 31, 2024, the anticipated funding for one of its other investments was not secured within the expected timeframe. As a result, the Company recorded impairment expense of $13.0 million for the three months ended March 31, 2024, which consisted of the full impairment of one of the Company’s other investments. The impairment expenses were recorded within impairment of other investments on the condensed consolidated statements of operations and comprehensive loss and as a reduction to the investment balances within other investments on the condensed consolidated balance sheets.

Other Investments

3 Months Ended

Mar. 31, 2025

Investments, All Other Investments [Abstract]

In prior years the Company made minority ownership strategic investments. As of both March 31, 2025 and December 31, 2024, the aggregate carrying amount of the Company’s strategic investments in non-publicly traded companies was $19.0 million. These investments are measured at initial cost, minus impairment, if any, and plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Cumulative impairments of strategic investments in equity investments without readily determinable fair values still held as of both March 31, 2025 and December 31, 2024 were $23.0 million, reflecting the full impairment of two of the Company’s other investments in the first quarters of 2023 and 2024.

As a part of the acquisition of each of the Company’s other investments, the Company determines whether an investment or other interest is considered a variable interest. As of both March 31, 2025 and December 31, 2024, the Company held an interest in one entity that was concluded to be a variable interest for which the Company was not the primary beneficiary as the Company did not have the power to direct the activities that most significantly impact the economic performance of the variable interest entity. As of both March 31, 2025 and December 31, 2024, the carrying value and maximum exposure to loss of the Company’s variable interests was zero.

In connection with the preparation of the financial statements for the three months ended March 31, 2024, the Company performed a qualitative assessment of potential indicators of impairment and determined that indicators existed for one of its other investments with a carrying amount of $13.0 million. During the three months ended March 31, 2024, the anticipated funding for one of its other investments was not secured within the expected timeframe. As a result, the Company recorded impairment expense of $13.0 million for the three months ended March 31, 2024, which consisted of the full impairment of one of the Company’s other investments. The impairment expenses were recorded within impairment of other investments on the condensed consolidated statements of operations and comprehensive loss and as a reduction to the investment balances within other investments on the condensed consolidated balance sheets.